Der hier verfügbare Newsfeed wird von unserem Content-Partner PR Newswire bereitgestellt. Es handelt sich dabei um einen der bedeutendsten und reichweitenstärksten Pressedienste, die Nachrichten, Pressemitteilungen und Multimedia-Inhalte an Medien, Journalisten und der Öffentlichkeit zur Verfügung stellen.
Der NewsWire-Hub ("X-Billboard") umfasst derzeit vier der wichtigsten internationalen Nachrichtenquellen und wird durch einen Börseninformationsservice ergänzt. Die einzelnen Newswire-Services ergänzen sich und bilden ein komplementäres Informationsangebot, mehr als drei Viertel der offiziellen Nachrichtenquellen ab, auf die sich Redaktionen weltweit bei ihrer Börsenberichterstattung stützen. Ihr Vorteil: Sie finden hier alles in einer Übersicht. Über die Steuerelemente können Sie zu den einzelnen Bereichen navigieren. Im Terminalview können Sie gezielt auf Unternehmensebene individuelle Recherchen durchführen.
F&G: 76
6.308,26 S&P · 18,93 Vola-Index · 118.341,71 BTC · 1,16230 EURUSD
Systemstatus: 111.906 Nachrichten wurden bislang erfolgreich verarbeitet
EXCHANGE NEWSBOARD
                              
NEWSWIRE INFOBOARD
                              
PR Newswire ist eine wichtige Nachrichtenquelle, die über das X-Billboard abgerufen werden kann. Sie ist Teil des Newswire-Hub, der für Börsianer wichtige internationalen Nachrichtenquellen an einem zentralen Ort bündelt. Wer sich schnell einen Überblick verschaffen will, kann sich bequem durch die Headlines scrollen. Wer sich detailliert mit den Nachrichten auseinandersetzen möchte, kann über die Detailansichten der Info-Cards direkt auf die jeweilige Nachricht und weitere Analysewerkzeuge zugreifen.
NEWS
EXPLORER
US58933Y1055
Letzte Aktualisierung: 21.07.2025 | 5AM
Kennen Sie bereits den neuen Terminal-View? Folgen Sie bei Interesse dem folgenden Link.
FIGI: BBG000BPD168
MRK

Merck & Company, Inc.
GICS: 35202010 · Sektor: Healthcare · Sub-Sektor: Drug Manufacturers—General
NAME
Merck & Company, Inc.
ISIN
US58933Y1055
TICKER
MRK
MIC
XNYS
REUTERS
MRK.N
BLOOMBERG
MRK US
Mo., 07.07.2025       Merck & Co.

NetworkNewsWire Editorial Coverage

NEW YORK, July 7, 2025 /PRNewswire/ -- An estimated 20 million people are diagnosed annually with cancer, while cancer kills almost 10 million people a year worldwide (https://ibn.fm/dyQrw) with these numbers expected to grow. The American Cancer Society projects that by 2050, 35 million people will be diagnosed with cancer every year. Despite significant progress made in treating the disease, there is still a desperate need — and an enormous market potential — for new and more effective cancer drugs. Calidi Biotherapeutics Inc. (NYSE American: CLDI) (Profile) is committed to developing a novel approach to treating cancer through the precise delivery of genetic medicines to both primary tumors and metastatic sites of disease. This cutting-edge platform, which harnesses engineered viruses that can target sites of cancer in the body and deliver potent genetic medicines to attack tumors, has the potential to revolutionize the way cancer is treated. And while cancer is the initial focus for Calidi, the company has also begun to assess the potential of this technology in other areas of large unmet need such as autoimmune disease. Calidi is joining an elite group of high-quality companies focused on making a difference in the world of cancer and genetic medicines, including Regeneron Pharmaceuticals Inc. (NASDAQ: REGN), CG Oncology Inc. (NASDAQ: CGON), Roche (OTCQX: RHHBY) and Merck & Co. Inc. (NYSE: MRK).

Mo., 07.07.2025       Merck & Co.

NetworkNewsWire Editorial Coverage

NEW YORK, July 7, 2025 /CNW/ -- An estimated 20 million people are diagnosed annually with cancer, while cancer kills almost 10 million people a year worldwide (https://ibn.fm/dyQrw) with these numbers expected to grow. The American Cancer Society projects that by 2050, 35 million people will be diagnosed with cancer every year. Despite significant progress made in treating the disease, there is still a desperate need — and an enormous market potential — for new and more effective cancer drugs. Calidi Biotherapeutics Inc. (NYSE American: CLDI) (Profile) is committed to developing a novel approach to treating cancer through the precise delivery of genetic medicines to both primary tumors and metastatic sites of disease. This cutting-edge platform, which harnesses engineered viruses that can target sites of cancer in the body and deliver potent genetic medicines to attack tumors, has the potential to revolutionize the way cancer is treated. And while cancer is the initial focus for Calidi, the company has also begun to assess the potential of this technology in other areas of large unmet need such as autoimmune disease. Calidi is joining an elite group of high-quality companies focused on making a difference in the world of cancer and genetic medicines, including Regeneron Pharmaceuticals Inc. (NASDAQ: REGN), CG Oncology Inc. (NASDAQ: CGON), Roche (OTCQX: RHHBY) and Merck & Co. Inc. (NYSE: MRK).

Mo., 07.07.2025       Merck & Co.

NetworkNewsWire Editorial Coverage

NEW YORK, July 7, 2025 /PRNewswire/ -- An estimated 20 million people are diagnosed annually with cancer, while cancer kills almost 10 million people a year worldwide (https://ibn.fm/dyQrw) with these numbers expected to grow. The American Cancer Society projects that by 2050, 35 million people will be diagnosed with cancer every year. Despite significant progress made in treating the disease, there is still a desperate need — and an enormous market potential — for new and more effective cancer drugs. Calidi Biotherapeutics Inc. (NYSE American: CLDI) (Profile) is committed to developing a novel approach to treating cancer through the precise delivery of genetic medicines to both primary tumors and metastatic sites of disease. This cutting-edge platform, which harnesses engineered viruses that can target sites of cancer in the body and deliver potent genetic medicines to attack tumors, has the potential to revolutionize the way cancer is treated. And while cancer is the initial focus for Calidi, the company has also begun to assess the potential of this technology in other areas of large unmet need such as autoimmune disease. Calidi is joining an elite group of high-quality companies focused on making a difference in the world of cancer and genetic medicines, including Regeneron Pharmaceuticals Inc. (NASDAQ: REGN), CG Oncology Inc. (NASDAQ: CGON), Roche (OTCQX: RHHBY) and Merck & Co. Inc. (NYSE: MRK).

Silent Ad
Mo., 07.07.2025       Merck & Co.

NetworkNewsWire Editorial Coverage

NEW YORK, July 7, 2025 /CNW/ -- An estimated 20 million people are diagnosed annually with cancer, while cancer kills almost 10 million people a year worldwide (https://ibn.fm/dyQrw) with these numbers expected to grow. The American Cancer Society projects that by 2050, 35 million people will be diagnosed with cancer every year. Despite significant progress made in treating the disease, there is still a desperate need — and an enormous market potential — for new and more effective cancer drugs. Calidi Biotherapeutics Inc. (NYSE American: CLDI) (Profile) is committed to developing a novel approach to treating cancer through the precise delivery of genetic medicines to both primary tumors and metastatic sites of disease. This cutting-edge platform, which harnesses engineered viruses that can target sites of cancer in the body and deliver potent genetic medicines to attack tumors, has the potential to revolutionize the way cancer is treated. And while cancer is the initial focus for Calidi, the company has also begun to assess the potential of this technology in other areas of large unmet need such as autoimmune disease. Calidi is joining an elite group of high-quality companies focused on making a difference in the world of cancer and genetic medicines, including Regeneron Pharmaceuticals Inc. (NASDAQ: REGN), Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX), Roche (OTCQX: RHHBY) and Merck & Co. Inc. (NYSE: MRK).

Mo., 07.07.2025       Merck & Co.

NetworkNewsWire Editorial Coverage

NEW YORK, July 7, 2025 /PRNewswire/ -- An estimated 20 million people are diagnosed annually with cancer, while cancer kills almost 10 million people a year worldwide (https://ibn.fm/dyQrw) with these numbers expected to grow. The American Cancer Society projects that by 2050, 35 million people will be diagnosed with cancer every year. Despite significant progress made in treating the disease, there is still a desperate need — and an enormous market potential — for new and more effective cancer drugs. Calidi Biotherapeutics Inc. (NYSE American: CLDI) (Profile) is committed to developing a novel approach to treating cancer through the precise delivery of genetic medicines to both primary tumors and metastatic sites of disease. This cutting-edge platform, which harnesses engineered viruses that can target sites of cancer in the body and deliver potent genetic medicines to attack tumors, has the potential to revolutionize the way cancer is treated. And while cancer is the initial focus for Calidi, the company has also begun to assess the potential of this technology in other areas of large unmet need such as autoimmune disease. Calidi is joining an elite group of high-quality companies focused on making a difference in the world of cancer and genetic medicines, including Regeneron Pharmaceuticals Inc. (NASDAQ: REGN), Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX), Roche (OTCQX: RHHBY) and Merck & Co. Inc. (NYSE: MRK).

Mo., 07.07.2025       Merck & Co.

NetworkNewsWire Editorial Coverage

NEW YORK, July 7, 2025 /PRNewswire/ -- An estimated 20 million people are diagnosed annually with cancer, while cancer kills almost 10 million people a year worldwide (https://ibn.fm/dyQrw) with these numbers expected to grow. The American Cancer Society projects that by 2050, 35 million people will be diagnosed with cancer every year. Despite significant progress made in treating the disease, there is still a desperate need — and an enormous market potential — for new and more effective cancer drugs. Calidi Biotherapeutics Inc. (NYSE American: CLDI) (Profile) is committed to developing a novel approach to treating cancer through the precise delivery of genetic medicines to both primary tumors and metastatic sites of disease. This cutting-edge platform, which harnesses engineered viruses that can target sites of cancer in the body and deliver potent genetic medicines to attack tumors, has the potential to revolutionize the way cancer is treated. And while cancer is the initial focus for Calidi, the company has also begun to assess the potential of this technology in other areas of large unmet need such as autoimmune disease. Calidi is joining an elite group of high-quality companies focused on making a difference in the world of cancer and genetic medicines, including Regeneron Pharmaceuticals Inc. (NASDAQ: REGN), Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX), Roche (OTCQX: RHHBY) and Merck & Co. Inc. (NYSE: MRK).

Di., 22.04.2025       Merck & Co.

Approval is based on the results from the Phase 3 CCTG IND.227/KEYNOTE-483 trial

KIRKLAND, QC, April 22, 2025 /CNW/ -- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that Health Canada has approved KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy, in combination with pemetrexed and platinum chemotherapy, for the first-line treatment of adult patients with unresectable advanced or metastatic malignant pleural mesothelioma (MPM). The approval is based on data from the pivotal Phase 3 IND.227/KEYNOTE-483 trial, which demonstrated a statistically significant improvement in overall survival (OS), progression-free survival (PFS) and overall response rate (ORR) in patients randomized to KEYTRUDA® in combination with chemotherapy compared with patients randomized to chemotherapy alone. This pivotal trial was led by the Canadian Cancer Trials Group (CCTG) in collaboration with the National Cancer Institute of Naples (NCIN) and the Intergroupe Francophone de Cancérologie Thoracique (IFCT).

Mo., 14.04.2025       Merck & Co.

NEW YORK, April 14, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Merck & Co., Inc. ("Merck" or the "Company") (NYSE: MRK). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

Mo., 14.04.2025       Merck & Co.

LOS ANGELES, April 13, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Merck & Co., Inc. ("Merck" or "the Company") (NYSE: MRK) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Investors who purchased the Company's securities between February 3, 2022, and February 3, 2025, inclusive (the "Class Period"), are encouraged to contact the firm before April 14, 2025.  

So., 13.04.2025       Merck & Co.

NEW YORK, April 13, 2025 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Merck & Co., Inc. (NYSE: MRK) between February 3, 2022 and February 3, 2025, both dates inclusive (the "Class Period"), of the important April 14, 2025 lead plaintiff deadline.

So what: If you purchased Merck securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

Silent Ad
Fr., 11.04.2025       Merck & Co.

NEW YORK, April 11, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Merck & Co., Inc. ("Merck" or the "Company") (NYSE: MRK) of a class action securities lawsuit.

CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Merck investors who were adversely affected by alleged securities fraud between February 3, 2022 and February 3, 2025. Follow the link below to get more information and be contacted by a member of our team:

Do., 10.04.2025       Merck & Co.

LOS ANGELES, April 10, 2025 /PRNewswire/ -- Glancy Prongay & Murray LLP announces that investors with losses have opportunity to lead the securities fraud class action lawsuit against Merck & Co ("Merck" or the "Company") (NYSE: MRK).

IF YOU SUFFERED A LOSS ON YOUR MERCK INVESTMENTS, CLICK HERE BEFORE APRIL 14, 2025 (LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE SECURITIES FRAUD LAWSUIT

Do., 10.04.2025       Merck & Co.

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Merck To Contact Him Directly To Discuss Their Options

If you purchased or acquired securities in Merck between February 3, 2022 and February 3, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

[You may also click here for additional information]

NEW YORK, April 10, 2025 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Merck & Co., Inc. ("Merck" or the "Company") (NYSE: MRK) and reminds investors of the April 14, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Do., 10.04.2025       Merck & Co.

NEW YORK, April 10, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Merck & Co., Inc. (NYSE: MRK).

Shareholders who purchased shares of MRK during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.

CONTACT US HERE:

Di., 08.04.2025       Merck & Co.

NEW YORK, April 8, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Merck & Co., Inc. ("Merck" or the "Company") (NYSE: MRK).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

Di., 08.04.2025       Merck & Co.

NEW YORK, April 8, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Merck & Co., Inc. ("Merck" or the "Company") (NYSE: MRK) of a class action securities lawsuit.

CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Merck investors who were adversely affected by alleged securities fraud between February 3, 2022 and February 3, 2025. Follow the link below to get more information and be contacted by a member of our team:

Mo., 07.04.2025       Merck & Co.

NEW YORK, April 7, 2025 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Merck & Co., Inc. (NYSE: MRK) between February 3, 2022 and February 3, 2025, both dates inclusive (the "Class Period"). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 14, 2025.

Mo., 07.04.2025       Merck & Co.

NEW YORK, April 7, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Merck & Co., Inc. (NYSE: MRK).

Shareholders who purchased shares of MRK during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.

CONTACT US HERE:

https://securitiesclasslaw.com/securities/merck-co-inc-loss-submission-form/?id=140971&from=4

Fr., 04.04.2025       Merck & Co.

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Merck To Contact Him Directly To Discuss Their Options

If you suffered losses exceeding $100,000 in Merck between February 3, 2022 and February 3, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

[You may also click here for additional information]

NEW YORK, April 4, 2025 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Merck & Co., Inc. ("Merck" or the "Company") (NYSE: MRK) and reminds investors of the April 14, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Fr., 04.04.2025       Merck & Co.

BENSALEM, Pa., April 4, 2025 /PRNewswire/ -- The Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Merck & Co ("Merck" or the "Company") (NYSE: MRK).

IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN MERCK & CO (MRK), CONTACT THE LAW OFFICES OF HOWARD G. SMITH BEFORE APRIL 14, 2025 (LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE ONGOING SECURITIES FRAUD LAWSUIT.

Contact the Law Offices of Howard G. Smith to discuss your legal rights by email at howardsmith@howardsmithlaw.com, by telephone at (215) 638-4847 or visit our website at www.howardsmithlaw.com.

Silent Ad

Die hier zur Verfügung gestellten Informationen unterliegen keiner redaktionellen Bearbeitung. Die Aufbereitung erfolgt vollautomatisch und wird durch Zusatzinformationen und weiterführende Recherchemöglichkeiten angereichert. Ziel der Inhalte ist die schnelle und unkomplizierte Versorgung der Informationssuchenden mit den für sie relevanten Informationen. Durch eine Rückverlinkung auf den Informationsanbieter und -eigentümer ist sichergestellt, dass die hier aufbereiteten Daten bei Bedarf mit den Quellinformationen abgeglichen werden können. Das Newsboard zeigt keine Informationen in Echtzeit. Diese bitten wir bei Bedarf beim Börsenbetreiber abzurufen. Es besteht kein Anspruch auf Vollständigkeit. Hochverfügbarkeit kann nicht gewährleistet werden. Sollten Sie Fehler in der Funktionsweise bemerken, teilen Sie uns diese über das weiter unten befindliche Formular "Report a Bug" mit.

RAW DATA PROCESSING bedeutet, dass Rohdaten verarbeitet werden, ohne den Inhalt zu verändern. Um die Interpretation der Information im Sinne der Nutzbarkeit zu verbessern, werden die Daten ergänzt. 

Hinweis: Über das Newswire-Crosslink-Panel im oberen Bereich gelangen Sie schnell und bequem zu weiteren Informationsquellen. Im Terminalview sind die Nachrichten auf Unternehmensebene gefiltert und ermöglich darüber gezielte Recherchen.


Wir bedanken uns im Namen der Trading-Community bei den Betreibern der Handelsplätze für die Bereitstellung von Informationsdiensten.